Global Blood Therapeutics (GBT) Tops Q1 EPS by 4c

Global Blood Therapeutics (NASDAQ: GBT) reported Q1 EPS of ($1.26), $0.04 better than the analyst estimate of ($1.30). Revenue for the quarter came in at $55.16 million versus the consensus estimate of $56.14 million.

For earnings history and earnings-related data on Global Blood Therapeutics (GBT) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• CoStar Group acquires Zonda for $800M, adding new home data
• Bernstein remains bullish on SpaceX but sees challenges in telecom ambitions